The use of Operative Link on Gastritis Assessment (OLGA) and Operative Link on Gastritis Assessment based on Intestinal Metaplasia (OLGIM) staging system is recommended for identifying subjects at risk for developing gastric cancer; usually high-risk lesions are considered only as stages III and IV. Accumulating evidence suggests that incomplete intestinal metaplasia (IM) is important in the development of gastric cancer. Our aim has been to identify the prevalence of incomplete IM in patients with low-risk OLGA/OLGIM stages among a high-risk general population. Healthy adult volunteers aged 40–64 years were invited to undergo upper endoscopy within a regional GISTAR pilot study in Kazakhstan (n = 166). Gastric lesions were staged according to OLGA/OLGIM staging system. High iron diamine–alcian blue (HID-AB) was used for subtyping IM. IM prevalence overall was 45.8%. Incomplete IM was present in 52.6% (type II in 30.3% and type III in 22.3%), whereas complete IM was found in 47.4% individuals. The prevalence of OLGIM I and II stage were 39.8 and 4.8%, respectively, whereas OLGIM III was observed in 1.2%. The prevalence of incomplete IM in patients stratified to OLGIM I was 54.5% (type II in 31.8% and type III in 22.7%). High prevalence of incomplete IM was detected not only in subjects with extensive IM, but in those stratified as at the OLGIM I stage. Without IM subtyping, patients with high risk of gastric cancer development would be missed for surveillance.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
The manuscript with the results and data, figures, tables and text has been exclusively submitted for publication only to Virchows Archiv. The datasets used and/or analyzed in the present study are available from the corresponding author upon a reasonable request.
Pimentel-Nunes P, Libanio D, Marcos-Pinto R et al (2019) Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update. Endoscopy 51(4):365–388. https://doi.org/10.1055/a-0859-1883
Gupta S, Li D, El Serag HB, Davitkov P, Altayar O, Sultan S, Falck-Ytter Y, Mustafa RA (2020) AGA clinical practice guidelines on management of gastric intestinal metaplasia. Gastroenterology 158(3):693–702. https://doi.org/10.1053/j.gastro.2019.12.003
Rugge M, Capelle LG, Cappellesso R, Nitti D, Kuipers EJ (2013) Precancerous lesions in the stomach: from biology to clinical patient management. Best Pract Res Clin Gastroenterol 27(2):205–223. https://doi.org/10.1016/j.bpg.2012.12.007
Rugge M, Correa P, Dixon MF, Fiocca R, Hattori T, Lechago J, Leandro G, Price AB, Sipponen P, Solcia E, Watanabe H, Genta RM (2002) Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Pharmacol Ther 16(7):1249–1259. https://doi.org/10.1046/j.1365-2036.2002.01301.x
Cho SJ, Choi IJ, Kook MC, Nam BH, Kim CG, Lee JY, Ryu KW, Kim YW (2013) Staging of intestinal- and diffuse-type gastric cancers with the OLGA and OLGIM staging systems. Aliment Pharmacol Ther 38:1292–1302. https://doi.org/10.1111/apt.12515
de Vries AC, van Grieken NCT, Looman CWN, Casparie MK, de Vries E, Meijer GA, Kuipers EJ (2008) Gastric cancer risk in patients with premalignant gastric lesions a nationwide cohort study in the Netherlands. Gastroenterology 134(4):945–952. https://doi.org/10.1053/j.gastro.2008.01.071
de Vries AC, Haringsma J, de Vries RA, ter Borg F, Nagtzaam NM, Steyerberg EW, van Dekken H, Kuipers EJ (2009) The use of clinical, histologic, and serologic parameters to predict the intragastric extent of intestinal metaplasia: a recommendation for routine practice. Gastrointest Endosc 70:18–25. https://doi.org/10.1016/j.gie.2008.08.041
Correa P, Piazuelo MB, Wilson KT (2010) Pathology of gastric intestinal metaplasia: clinical implications. Am J Gastroenterol 105(3):493–498. https://doi.org/10.1038/ajg.2009.728
Sonnenberg A, Lash RH, Genta RM (2010) A national study of Helicobactor pylori infection in gastric biopsy specimens. Gastroenterology 139(6):1894–1901. https://doi.org/10.1053/j.gastro.2010.08.018
Wong BC, Lam SK, Wong WM et al (2004) Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 291:187–194. https://doi.org/10.1001/jama.291.2.187
Tulassay Z, Stolte M, Engstrand L et al (2010) Twelve-month endoscopic and histological analysis following proton-pump inhibitor based triple therapy in Helicobacter pylori-positive patients with gastric ulcers. Scand J Gastroenterol 45:1048–1058
Yeh LY, Raj M, Hassan S, Aziz SA, Othman NH, Mutum SS, Naik VR (2009) Chronic atrophic antral gastritis and risk of metaplasia and dysplasia in an area with low prevalence of Helicobacter pylori. Indian J Gastroenterol 28:49–52
Isajevs S, Liepniece-Karele I, Janciauskas D, Moisejevs G, Putnins V, Funka K, Kikuste I, Vanags A, Tolmanis I, Leja M (2014) Gastritis staging interobserver agreement by applying OLGA and OLGIM systems. Virchows Arch 464(4):403–417. https://doi.org/10.1007/s00428-014-1544-3
Correa P, Haenszel W, Cuello C, Zavala D, Fontham E, Zarama G, Tannenbaum S, Collazos T, Ruiz B (1990) Gastric precancerous process in a high risk population: cross-sectional studies. Cancer Res 50:4731–4736
Filipe MI, Munoz N, Matko I, Kato I, Pompe-Kirn V, Jutersek A, Teuchmann S, Benz M, Prijon T (1994) Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer 57:324–329
Shah SC, Gawron AJ, Mustafa RA, Piazuelo MB (2020) Histologic subtyping of gastric intestinal metaplasia: overview and considerations for clinical practice. Gastroenterology 158(3):745–750. https://doi.org/10.1053/j.gastro.2019.12.004
Gonzalez CA, Sanz-Anquela JM, Companioni O et al (2016) Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: results of the Spanish follow-up study. J Gastroenterol Hepatol 31:953–958. https://doi.org/10.1111/jgh.13249
Song H, Ekheden IG, Zheng Z, Ericsson J, Nyrén O (2015) Ye W (2015) Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. BMJ 351:h3867. https://doi.org/10.1136/bmj.h3867
Shichijo S, Hirata Y, Niikura R, Hayakawa Y, Yamada A, Ushiku T, Fukayama M, Koike K (2016) Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication. Gastrointest Endosc 84:618–624. https://doi.org/10.1016/j.gie.2016.03.791
Matsukauma A, Mori M (1990) Sulphomucin-secreting intestinal metaplasia in the human gastric mucosa. Cancer 66:689–694
You WC, Li JY, Blot WJ et al (1999) Evolution of precancerous lesions in a rural Chinese population at high risk of gastric cancer. Int J Cancer 83:615–619. https://doi.org/10.1002/(SICI)1097-0215(19991126)83:5%3c615::AID-IJC8%3e3.0.CO;2-L
Filipe MI, Muñoz N, Matko I, Kato I, Pompe-Kirn V, Jutersek A, Teuchmann S, Benz M, Prijon T (1994) Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer 57:324–329. https://doi.org/10.1002/ijc.2910570306
Rokkas T, Filipe MI, Sladen GE (1991) Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. Gut 32:1110–1113. https://doi.org/10.1136/gut.32.10.1110
Conchillo JM, Houben G, de Bruïne A, Stockbrügger R (2001) Is type III intestinal metaplasia an obligatory precancerous lesion in intestinal- type gastric carcinoma? Eur J Cancer Prev 10:307–312. https://doi.org/10.1097/00008469-200108000-00003
Kang KP, Lee HS, Kim N, Kang HM, Park YS, Lee DH, Choe G, Kim JS, Jung HC, Song IS (2009) Role of intestinal metaplasia subtyping in the risk of gastric cancer in Korea. J Gastroenterol Hepatol 24:140–148. https://doi.org/10.1111/j.1440-1746.2008.05546.x
González CA, Sanz-Anquela JM, Gisbert JP, Correa P (2013) Utility of subtyping intestinal metaplasia as marker of gastric cancer risk: a review of the evidence. Int J Cancer 133:1023–1032. https://doi.org/10.1002/ijc.28003
González CA, Pardo ML, Liso JM, Alonso P, Bonet C, Garcia RM, Sala N, Capella G, Sanz-Anquela JM (2010) Gastric cancer occurrence in preneoplastic lesions: a long-term follow-up in a high-risk area in Spain. Int J Cancer 127:2654–2660. https://doi.org/10.1002/ijc.25273
Dinis-Ribeiro M, Lopes C, da Costa-Pereira A, Guilherme M, Barbosa J, Lomba-Viana H, Silva R, Moreira-Dias L (2004) A follow up model for patients with atrophic chronic gastritis and intestinal metaplasia. J Clin Pathol 57:177–182. https://doi.org/10.1136/jcp.2003.11270
Lin CK, Lai KH, Lo GH, Cheng JS, Hsu PI, Mok KT, Tseng HH (2001) Cathepsin E and subtypes of intestinal metaplasia in carcinogenesis of the human stomach. Zhonghua Yi Xue Za Zhi 64:331–336
Rokkas T, Sechopoulos P, Pistiolas D, Margantinis G, Koukoulis G (2010) Helicobacter pylori infection and gastric histology in first degree relatives of gastric cancer patients a meta-analysis. Eur J Gastroenterol Hepatol 22:1128–1133. https://doi.org/10.1097/MEG.0b013e3283398d37
Silva S, Filipe MI, Pinho A (1990) Variants of intestinal metaplasia in the evolution of chronic atrophic gastritis and gastric ulcer. A follow up study Gut 31:1097–1104. https://doi.org/10.1136/gut.31.10.1097
Gawron AJ, Shah SC, Altayar O, Davitkov P, Morgan D, Turner K, Mustafa RA (2020) AGA technical review on gastric intestinal metaplasia—natural history and clinical outcomes. Gastroenterology 158:709–735. https://doi.org/10.1053/j.gastro.2019.12.001
Umarova G, Mamyrbayev A, Bermagambetova S, Baspakova A, Satybaldieva U, Sabyrakhmetova V, Abilov T, Sultanova G, Uraz R (2016) Morbidity disability and death rates of the population due to malignant neoplasms in Uralsk city in the republic of Kazakhstan. Asian Pac J Cancer Prev 17(12):5159–5164. https://doi.org/10.22034/APJCP.2016.17.12.5159
Leja M, Park JY, Murillo R, et al (2017) Multicentric randomised study of Helicobacter pylori eradication and pepsinogen testing for prevention of gastric cancer mortality: the GISTAR study. BMJ Open 11;7(8):e016999. https://doi.org/10.1136/bmjopen-2017-016999
Mezmale L, Isajevs S, Bogdanova I et al (2019) Prevalence of atrophic gastritis in Kazakhstan and the accuracy of pepsinogen tests to detect gastric mucosal atrophy. Asian Pac J Cancer Prev 20(12):3825–3829. https://doi.org/10.31557/APJCP.2019.20.12.3825
Mezmale L, Polaka I, Rudzite D et al (2021) Prevalence and potential risk factors of Helicobacter pylori infection among asymptomatic individuals in Kazakhstan. Asian Pac J Cancer Prev 22(2):597–602. https://doi.org/10.31557/APJCP.2021.22.2.597
Kulmambetova GN, Imanbekova MK, Logvinenko AA, Sukashev AT, Filipenko ML, Ramanculov EM (2014) Association of cytokine gene polymorphisms with gastritis in a Kazakh population. Asian Pac J Cancer Prev 15:7763–7768
Benberin V, Bektayeva R, Karabayeva R, Lebedev A, Akemeyeva K, Paloheimo L, Syrjänen K (2013) Prevalence of H. pylori infection and atrophic gastritis among symptomatic and dyspeptic adults in Kazakhstan. A hospital-based screening study using a panel of serum biomarkers. Anticancer Res 33:4595–4602
de Vries AC, Meijer GA, Looman CW, Casparie MK, Hansen BE, van Grieken NC, Kuipers EJ (2007) Epidemiological trends of pre-malignant gastric lesions: a long-term nationwide study in the Netherlands. Gut 56:1665–1670. https://doi.org/10.1136/gut.2007.127167
Marques-Silva L, Areia M, Elvas L, Dinis-Ribeiro M (2014) Prevalence of gastric precancerous conditions: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 26:378–387. https://doi.org/10.1097/MEG.0000000000000065
Eriksson NK, Karkkainen PA, Farkkila MA, Arkkila PE (2008) Prevalence and distribution of gastric intestinal metaplasia and its subtypes. Dig Liver Dis 40:355–360. https://doi.org/10.1016/j.dld.2007.12.012
Ozdil K, Sahin A, Kahraman R, Yuzbasioglu B, Demirdag H, Calhan T, Yuzbasioglu B, Demirdag H, Calhan T, Muberra S, Yilmaz H, Sokmen M (2010) Current prevalence of intestinal metaplasia and Helicobacter pylori infection in dyspeptic adult patients from Turkey. Hepatogastroenterology 57:1563–1566
Rugge M, Meggio A, Pravadelli C, Barbareschi M, Fassan M, Gentilini M, Zorzi M, De Pretis G, Graham DY, Genta RM (2019) Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients. Gut 68(1):11–17. https://doi.org/10.1136/gutjnl-2017-314600
Tava F, Luinetti O, Ghigna MR, AlvisiC PM, Trespi E, Klersy C, Fratti C, Fiocca R, Solcia E (2006) Type or extension of intestinal metaplasia and immature/atypical “indefinite-for dysplasia” lesions as predictors of gastric neoplasia. Hum Pathol 37:1489–1497. https://doi.org/10.1016/j.humpath.2006.05.012
We acknowledge Aiga Rudule for the GISTAR regional pilot study managment in Kazakhstan and Ilze Polaka for assistance in statistical analysis. The infrastructure for IM subtyping has been provided by the Academic Histology laboratory, Riga, Latvia. The assistance of BioMedES UK (www.biomedes.biz) in the final drafting of this paper is acknowledged.
The work was supported in part from the grant of ERDF “H. pylori risk stratification, optimization of management and interplay with other gastric microbiota within major cancer prevention studies of international scope”; University of Latvia grant “Development, validation and implementation of an histochemical method for gastric intestinal metaplasia subtyping to access the risk of gastric cancer”, and project No. AP05133849 “Decreasing the burden of gastric cancer in Kazakhstan: evaluation of the existing situation and search for improvement possibilities” Ministry of Education and Science of the Republic of Kazakhstan.
The study protocol (version 4.5, revised on 7 September 2015) was approved by the Ethics Committee of the International Agency for Research on Cancer (IEC 12–36), and the National Ethics Committees in Latvia, the Ethics Committee of Riga East University Support Foundation (No.14-A/13), and the Central Medical Ethics Committee (No. 01–29.1/11). The protocol is registered in the clinicaltrials.gov database (NCT02047994).
Consent to participate
All patients signed informed consent to participate in the study.
Consent for publication
The manucript and data has been submitted for publication to only Virchows Archiv.
Conflict of interest
The authors declare that they have no conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Isajevs, S., Savcenko, S., Liepniece-Karele, I. et al. High-risk individuals for gastric cancer would be missed for surveillance without subtyping of intestinal metaplasia. Virchows Arch 479, 679–686 (2021). https://doi.org/10.1007/s00428-021-03116-3
- Gastric cancer
- OLGIM intestinal metaplasia
- Risk stratification